A nasal spray could be a treatment for optic neuritis.

Optic neuritis is the most common presenting sign of MS and up to 60% of patients develop permanent visual deficits.

What is the drug?
It’s called ST266 and contains multiple anti-inflammatory cytokines and growth factors.
Intranasal delivery of this drug in mice showed it accumulated at therapeutic levels in optic nerve and in the vitreous and thus reduced visual dysfunction and prevented ganglion cell loss.

The authors state these results suggest intranasal delivery “should be explored as a potentially safer, easier and noninvasive method of delivering existing therapies that could lead to significant changes in current treatment practices”.

Jaclyn Garlich
Dr. Garlich graduated from the New England College of Optometry in 2010 and completed a residency in primary care and ocular disease at the St. Louis VA. In 2013, she developed an optometry clinical reference mobile app available in the iTunes store. In 2016, she founded 20/20 Glance, a weekly optometry newsletter that gives a rundown on clinically relevant optometry news in an easy to digest format.

Get in Touch

LEAVE A REPLY

Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts